Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Jun 2019 to Jun 2024
Diagnostic Products Corporation (NYSE:DP) announced
today that it has established a record date for a special meeting of
its shareholders to consider and vote upon the proposal to approve the
Agreement and Plan of Merger, dated as of April 26, 2006, by and among
Siemens Medical Solutions USA, Inc., Dresden Acquisition Corporation
(a wholly owned subsidiary of Siemens Medical Solutions USA) and DPC.
DPC shareholders of record at the close of business on Monday, June
19, 2006 will be entitled to notice of, and to vote at, the special
meeting, which will be held at 10:00 a.m. local time on Thursday, July
27, 2006 at 5210 Pacific Concourse Drive, Los Angeles, California.
A definitive proxy statement containing information about the
special meeting and the proposed merger will be filed with the
Securities and Exchange Commission and a copy of the definitive proxy
statement, along with other voting materials and instructions, will be
mailed to each shareholder of record as of the record date.
Shareholders are encouraged to read the definitive proxy statement
when it becomes available as it contains important information about
the transaction.
About Diagnostic Products Corporation
Diagnostic Products Corporation, founded in 1971, is a leader in
the global in vitro diagnostics market. DPC's product offering
includes the widely accepted IMMULITE(R) series of immunoassay
systems, more than 75 immunoassays and an expanding menu of essential
specific allergens and allergy panels that are run just like other
immunoassays. DPC also designs and manufactures automated laboratory
instrumentation and automation solutions that provide fast, accurate
results while enabling its customers to do "more with less" in a
leaner laboratory. DPC addresses the clinical chemistry and laboratory
automation needs of its customers through partnerships with
manufacturers of chemistry systems and reagents. DPC's combined
chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested. In
fiscal 2005 (December 31), DPC reported sales of $481 million and
operating income of $96 million. Additional information can be found
at DPC's website at www.dpcweb.com.
DPC has filed a preliminary proxy statement and will file a
definitive proxy statement and other documents regarding the proposed
merger described in this communication with the Securities and
Exchange Commission. Shareholders are urged to read the definitive
proxy statement when it becomes available, because it will contain
important information about the transaction. A copy of the definitive
proxy statement, along with other voting materials and instructions,
will be mailed to each shareholder of record as of the record date.
Investors and shareholders may obtain a free copy of the definitive
proxy statement (when available) and other documents filed by DPC with
the SEC at the SEC's website at www.sec.gov. The definitive proxy
statement and other relevant documents may also be obtained free of
cost by directing a request to DPC, 5210 Pacific Concourse Drive, Los
Angeles, California 90045, attention: Investor Relations (telephone
310-645-8200).
DPC and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the shareholders of
DPC in connection with the merger. Information about DPC and its
directors and executive officers can be found in DPC's Proxy
Statements and Annual Reports on Form 10-K filed with the SEC.
Additional information regarding the interests of those persons in the
proposed merger may be obtained by reading the proxy statement when it
becomes available. Except for the historical information contained
herein, this press release contains forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially. These factors include governmental or other action
relating to DPC's Chinese affiliate; the rate of customer demand for
DPC's products; DPC's ability to successfully market new and existing
products; its dependence on certain suppliers; domestic and foreign
government regulation; its ability to keep abreast of technological
innovations and to translate them into new products; competition;
political and economic instability in certain markets including the
movements of foreign currencies relative to the dollar; and other
risks and uncertainties disclosed from time to time in DPC's SEC
reports and filings.